Vanguard Therapeutics Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 4

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $1.68M

  • Investors
  • 3

Vanguard Therapeutics General Information

Description

Developer of drug therapy intended for sickle cell disease. The company's oral drug blocks the cell adhesion molecule P-selectin and addresses the problem of sickle red blood cells sticking to the vascular endothelium, enabling doctors to improve blood flow, mitigate acute painful crises, and improve the quality of life of patients with sickle cell disease.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Drug Discovery
Corporate Office
  • 108 Eagle Trace Drive
  • Half Moon Bay, CA 94019
  • United States
+1 (415) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vanguard Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant 01-Jan-2017 $1.68M Completed Generating Revenue
4. Grant 01-Jan-2016 00.000 Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2015 Completed Generating Revenue
2. Accelerator/Incubator 01-Apr-2014 Completed Generating Revenue
1. Grant 01-Jan-2014 $562K Completed Generating Revenue
To view Vanguard Therapeutics’s complete valuation and funding history, request access »

Vanguard Therapeutics Executive Team (1)

Name Title Board Seat Contact Info
Stephen Embury MD Founder, Chief Executive Officer & Chairman
To view Vanguard Therapeutics’s complete executive team members history, request access »

Vanguard Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vanguard Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
BayBio FAST Accelerator/Incubator 000 0000 000000 0
QB3 Accelerator/Incubator 000 0000 000000 0
U.S. Department of Health and Human Services Government 000 0000 000000 0
To view Vanguard Therapeutics’s complete investors history, request access »

Vanguard Therapeutics FAQs

  • When was Vanguard Therapeutics founded?

    Vanguard Therapeutics was founded in 2009.

  • Who is the founder of Vanguard Therapeutics?

    Stephen Embury MD is the founder of Vanguard Therapeutics.

  • Who is the CEO of Vanguard Therapeutics?

    Stephen Embury MD is the CEO of Vanguard Therapeutics.

  • Where is Vanguard Therapeutics headquartered?

    Vanguard Therapeutics is headquartered in Half Moon Bay, CA.

  • What is the size of Vanguard Therapeutics?

    Vanguard Therapeutics has 4 total employees.

  • What industry is Vanguard Therapeutics in?

    Vanguard Therapeutics’s primary industry is Drug Discovery.

  • Is Vanguard Therapeutics a private or public company?

    Vanguard Therapeutics is a Private company.

  • What is Vanguard Therapeutics’s current revenue?

    The current revenue for Vanguard Therapeutics is 000000.

  • Who are Vanguard Therapeutics’s investors?

    BayBio FAST, QB3, and U.S. Department of Health and Human Services have invested in Vanguard Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »